A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

December 31, 2027

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG

JMKX001899

JMKX001899 tablet administered orally daily.

DRUG

IN10018

IN10018 tablet administered orally daily.

DRUG

Chemotherapy: Pemetrexed

IV infusion once every 3 weeks

DRUG

Carboplatin

IV infusion once every 3 weeks, 4 Cycles

Trial Locations (1)

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou